The results revealed that in patients with stage IIB to IIIA, EGFR mutation-positive NSCLC, disease-free survival at 24 months was significantly longer for those receiving Osimertinib (90%) compared to the placebo group (44%). This evidence concerns the gene EGFR and non-small cell lung carcinoma.